These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30304563)

  • 21. Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant.
    Merritt R; Hayman MJ; Agazie YM
    Biochim Biophys Acta; 2006 Jan; 1763(1):45-56. PubMed ID: 16413071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of insulin-stimulated glycogen synthesis by Src Homology Phosphatase 2.
    Ouwens DM; van der Zon GC; Maassen JA
    Mol Cell Endocrinol; 2001 Apr; 175(1-2):131-40. PubMed ID: 11325523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep mutational scanning of a multi-domain signaling protein reveals mechanisms of regulation and pathogenicity.
    Jiang Z; van Vlimmeren AE; Karandur D; Semmelman A; Shah NH
    bioRxiv; 2024 Nov; ():. PubMed ID: 39091798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
    Pannone L; Bocchinfuso G; Flex E; Rossi C; Baldassarre G; Lissewski C; Pantaleoni F; Consoli F; Lepri F; Magliozzi M; Anselmi M; Delle Vigne S; Sorge G; Karaer K; Cuturilo G; Sartorio A; Tinschert S; Accadia M; Digilio MC; Zampino G; De Luca A; Cavé H; Zenker M; Gelb BD; Dallapiccola B; Stella L; Ferrero GB; Martinelli S; Tartaglia M
    Hum Mutat; 2017 Apr; 38(4):451-459. PubMed ID: 28074573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment.
    Farrokhzadeh A; Akher FB; Soliman MES
    Appl Biochem Biotechnol; 2019 May; 188(1):260-281. PubMed ID: 30430347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
    Krenz M; Yutzey KE; Robbins J
    Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2.
    Fairlie WD; De Souza D; Nicola NA; Baca M
    Biochem J; 2003 Jun; 372(Pt 2):495-502. PubMed ID: 12593670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
    Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
    Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
    Jopling C; van Geemen D; den Hertog J
    PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
    Chen L; Sung SS; Yip ML; Lawrence HR; Ren Y; Guida WC; Sebti SM; Lawrence NJ; Wu J
    Mol Pharmacol; 2006 Aug; 70(2):562-70. PubMed ID: 16717135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
    Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
    J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on the allosteric activation mechanism of SHP2
    Liu L; Cheng Y; Zhang Z; Li J; Geng Y; Li Q; Luo D; Liang L; Liu W; Hu J; Ouyang W
    Phys Chem Chem Phys; 2023 Sep; 25(35):23588-23601. PubMed ID: 37621251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme.
    Dong H; Zonta F; Wang S; Song K; He X; He M; Nie Y; Li S
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29278368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
    SarathKumar B; Lakshmi BS
    J Mol Model; 2019 Aug; 25(9):272. PubMed ID: 31451955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based kinetic models of modular signaling protein function: focus on Shp2.
    Barua D; Faeder JR; Haugh JM
    Biophys J; 2007 Apr; 92(7):2290-300. PubMed ID: 17208977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.